Kalaris Therapeutics (KLRS) Non-Current Assets (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Non-Current Assets of $11.3 million for Q1 2026, up 1146.15% year-over-year from $910000.0 in Q1 2025, and up 287.43% quarter-over-quarter from $2.9 million in Q4 2025.
Kalaris Therapeutics (KLRS) Non-Current Assets (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Non-Current Assets history runs 8 years deep, the most recent figure standing at $11.3 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 1146.15% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $18.4 million (up 234.54% YoY), while the FY2025 annual figure was $2.9 million, down 17.69% from the prior year.
- Non-Current Assets for Q1 2026 stood at $11.3 million, up from $2.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $34.0 million in Q4 2022, with the low at $910000.0 in Q1 2025.
- The 5-year median for Non-Current Assets is $7.4 million (2024), against an average of $14.0 million.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets tumbled 96.48% in 2024, then jumped 1146.15% in 2026.
- Kalaris Therapeutics' Non-Current Assets stood at $34.0 million in 2022, then sank by 90.71% to $3.2 million in 2023, then climbed by 12.5% to $3.6 million in 2024, then dropped by 17.69% to $2.9 million in 2025, then surged by 287.43% to $11.3 million in 2026.
- Business Quant data shows KLRS's Non-Current Assets at $11.3 million in Q1 2026, $2.9 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | 3.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.62 Mn |
| Mar 31, 2026 | 11.34 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Sep 30, 2025 | 2.99 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 910,000.00 |
| Dec 31, 2024 | 3.56 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Dec 31, 2023 | 3.16 Mn |
| Sep 30, 2023 | 28.29 Mn |
| Jun 30, 2023 | 29.78 Mn |
| Mar 31, 2023 | 31.77 Mn |
| Dec 31, 2022 | 34.03 Mn |
| Sep 30, 2022 | 21.66 Mn |
| Jun 30, 2022 | 23.48 Mn |
| Mar 31, 2022 | 24.65 Mn |
| Dec 31, 2021 | 33.25 Mn |
| Sep 30, 2021 | 34.66 Mn |
| Jun 30, 2021 | 11.47 Mn |